Stock Analiz

Stoke Therapeutics, Inc. (STOK) financials: revenue, earnings and cash flow

Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$7M, a net margin of -3.7%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $28M and net income -$243M.

Free cash flow was $45M in fiscal 2025 and positive in 1 of the 8 years shown.

The diluted share count rose 8249% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2022: $12M20222023: $9M20232024: $37M20242025: $184M2025$184M
Net income
2018: -$13M20182019: -$32M20192020: -$52M20202021: -$86M20212022: -$101M20222023: -$105M20232024: -$89M20242025: -$7M2025-$7M
Free cash flow
2018: -$12M20182019: -$33M20192020: -$43M20202021: -$68M20212022: -$36M20222023: -$83M20232024: -$87M20242025: $45M2025$45M
EPS (diluted)
2018: $-17.6520182019: $-1.8020192020: $-1.5620202021: $-2.3420212022: $-2.6020222023: $-2.3820232024: $-1.6520242025: $-0.122025$-0.12

Income statement

Fiscal yearTTM20252024202320222021202020192018
Revenue$28M$184M$37M$9M$12M————
Gross profit—————————
Operating income-$258M-$21M-$101M-$115M-$104M-$86M-$53M-$36M-$13M
Net income-$243M-$7M-$89M-$105M-$101M-$86M-$52M-$32M-$13M
EPS (diluted)$-3.77$-0.12$-1.65$-2.38$-2.60$-2.34$-1.56$-1.80$-17.65
R&D$191M$138M$89M$82M$78M$54M$32M$24M$8M
Revenue growth—+404.5%+316.3%−29.2%—————

Cash flow

Fiscal yearTTM20252024202320222021202020192018
Operating cash flow-$210M$46M-$87M-$81M-$32M-$67M-$42M-$31M-$11M
Capital spending-$5M-$670000-$203000-$2M-$4M-$1M-$1M-$2M-$935000
Free cash flow-$216M$45M-$87M-$83M-$36M-$68M-$43M-$33M-$12M
Dividends paid—$0$0$0$0$0$0$0$0
Buybacks—————————
Stock-based pay$40M$32M$27M$25M$23M$16M$6M$2M$240000

Balance sheet

Fiscal yearTTM20252024202320222021202020192018
Cash—$285M$217M$201M$230M$220M$287M$222M$105M
Debt—$4M$5M$7M$5M$7M$1M$0$0
Equity—$352M$229M$160M$185M$218M$286M$224M$105M
Total assets—$418M$272M$228M$256M$239M$298M$229M$108M
Shares (diluted)68M59M54M44M39M37M33M18M1M

Margins and returns

Fiscal yearTTM20252024202320222021202020192018
Gross margin—————————
Operating margin-913.1%-11.2%-277.3%-1307.2%-841.2%————
Net margin-862.1%-3.7%-243.4%-1192.5%-814.7%————
FCF margin-764.7%24.3%-238.2%-941.7%-288.8%————
ROIC—-4.6%-34.2%-54.5%-43.4%-30.2%-14.6%-12.6%-9.6%
ROE—-1.9%-38.9%-65.6%-54.7%-39.4%-18.3%-14.4%-11.9%

Frequently asked questions

What is Stoke Therapeutics’s annual revenue?

$184M in fiscal 2025 and $28M over the twelve months to September 30, 2026.

How much profit does Stoke Therapeutics make?

Net income was -$7M in fiscal 2025 (net margin -3.7%).

Is Stoke Therapeutics’s revenue growing?

Yes: revenue rose 404.5% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.